Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity
Authors:
Open Access
- 13 October 2025
- journal article
- research article
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 18 (1) , 86
Abstract
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by the lack of ER, PR, and HER2 expression. Its aggressive behavior, high degree of tumor heterogeneity, and immunosuppressive tumor microenvironment (TME) are associated with poor clinical outcomes, rapid disease progression, and limited therapeutic options. Although chimeric antigen receptor (CAR)-engineered T cell therapy has shown certain promise, its applicability in TNBC is hindered by antigen escape, TME-mediated suppression, and the logistical constraints of autologous cell production. Methods: In this study, we employed hematopoietic stem and progenitor cell (HSPC) gene engineering and a feeder-free HSPC differentiation culture to generate allogeneic IL-15-enhanced, mesothelin-specific CAR-engineered invariant natural killer T (Allo15MCAR-NKT) cells. Results: These cells demonstrated robust and multifaceted antitumor activity against TNBC, mediated by CAR- and NK receptor-dependent cytotoxicity, as well as selective targeting of CD1d+ TME immunosuppressive cells through their TCR. In both orthotopic and metastatic TNBC xenograft models, Allo15MCAR-NKT cells demonstrated potent antitumor activity, associated with robust effector and cytotoxic phenotypes, low exhaustion, and a favorable safety profile without inducing graft-versus-host disease. Conclusions: Together, these results support Allo15MCAR-NKT cells as a next-generation, off-the-shelf immunotherapy with strong therapeutic potential for TNBC, particularly in the context of metastasis, immune evasion, and treatment resistance.Keywords
Funding Information
- University of California, Los Angeles (UCLA MIMG M. John Pickett Post-Doctoral Fellow Award, UCLA BSCRC Innovation Award)
- California Institute for Regenerative Medicine (DISC2-11157)
- U.S. Department of War (CA200456)
This publication has 136 references indexed in Scilit:
- Making memory at birth: understanding the differentiation of natural killer T cellsCurrent Opinion in Immunology, 2012
- Mesothelin, a novel immunotherapy target for triple negative breast cancerBreast Cancer Research and Treatment, 2012
- CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivoBlood, 2012
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJournal of Clinical Investigation, 2011
- EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysisJournal of Clinical Pathology, 2011
- Generation of functional NKT cells in vitro from embryonic stem cells bearing rearranged invariant Vα14-Jα18 TCRα geneBlood, 2010
- Engineering Artificial Antigen-presenting Cells to Express a Diverse Array of Co-stimulatory MoleculesMolecular Therapy, 2007
- The Biology of NKT CellsAnnual Review of Immunology, 2007
- TOWARD AN UNDERSTANDING OF NKT CELL BIOLOGY: Progress and ParadoxesAnnual Review of Immunology, 2005
- The duration of antigen receptor signalling determines CD4+ versus CD8+ T-cell lineage fateNature, 2000